ClinVar Miner

Submissions for variant NM_000257.4(MYH7):c.2105T>A (p.Ile702Asn) (rs397516132)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000628958 SCV000059414 likely pathogenic Hypertrophic cardiomyopathy 2014-02-06 criteria provided, single submitter clinical testing The Ile702Asn variant in MYH7 has been reported in 1 individual with DCM as well as 5 affected relatives (2 with DCM and 3 with HCM), with the possibility that the DCM in this family resulted from end-stage HCM (Bishara 2008, LMM unpublishe d data, pers. comm.). The variant was absent from large population studies and was predicted to be pathogenic using a computational tool clinically validated b y our laboratory. This tool's pathogenic prediction is estimated to be correct 9 4% of the time (Jordan 2011).In summary, this variant is likely to be pathogenic , though additional studies are required to fully establish its clinical signifi cance.
GeneDx RCV000158508 SCV000208443 likely pathogenic not provided 2014-05-23 criteria provided, single submitter clinical testing p.Ile702Asn (ATC>AAC): c.2105 T>A in exon 19 of the MYH7 gene (NM_000257.2). An I702N variant that is likely pathogenic was identified in the MYH7 gene. I702N in the MYH7 gene has been reported in an individual with HCM (Zou et al., 2013). I702N results in a non-conservative amino acid substitution of a non-polar Isoleucine with a polar Asparagine at a position that is well conserved across species. Consequently, in silico analysis predicts I702N is damaging to the protein structure/function. Mutations in nearby residues (N696S, V698A, C705W, P710H, P710R, R712L) have been reported in association with HCM, further supporting the functional importance of this region of the protein. Furthermore, the I702N variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Therefore, this variant is a strong candidate for a pathogenic mutation, however the possibility that it is a benign variant cannot be excluded. The variant is found in DCM,HCM,CARDIOMYOPATHY panel(s).
Invitae RCV000628958 SCV000749867 likely pathogenic Hypertrophic cardiomyopathy 2018-01-03 criteria provided, single submitter clinical testing This sequence change replaces isoleucine with asparagine at codon 702 of the MYH7 protein (p.Ile702Asn). The isoleucine residue is highly conserved and there is a large physicochemical difference between isoleucine and asparagine. This variant is not present in population databases (ExAC no frequency). This variant has been reported in an individual affected with hypertrophic cardiomyopathy (PMID: 25611685).  ClinVar contains an entry for this variant (Variation ID: 42880). A computational algorithm designed to assess the pathogenicity of variants in MYH7 with regard to hypertrophic cardiomyopathy predicted this sequence change to be deleterious. The algorithm has a sensitivity of 94% and a specificity of 89% (PMID: 21310275). This variant is found within a region of MYH7 between codons 181 and 937 that contains the majority of the myosin head domain. Missense variants in this region have been shown to be significantly overrepresented in individuals with hypertrophic cardiomyopathy (PMID: 27532257). A different missense substitution at this codon (p.Ile702Val) has been determined to be pathogenic (PMID: 23283745, 27247418, 27532257). This suggests that the isoleucine residue is critical for MYH7 protein function and that other missense substitutions at this position may also be pathogenic. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.